|
⚲
|
| Keyboard |
| Farallon Capital Management LLC
✚
|
|
|---|---|
| CRD # | 107322 |
| SEC # | 801-51763 |
| CIK # | 0000909661 |
| AUM | 52.08 B (2026-03-30) |
| Employees | 355 (36% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 415-421-2132 |
| Address | One Maritime Plaza San Francisco, CA 94111 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Tue, 30 Jun 2026 | Farallon Capital Management LLC Increases Stake in Centessa Phar — GuruFocus |
| Wed, 24 Jun 2026 | Farallon Capital Management Discloses Investment in Centessa with 6.1% Stake — TradingView |
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5: Fees and Compensation A. Fees and Compensation Management Fees Management fees payable to Farallon vary by Farallon Fund and are established pursuant to the Farallon Funds’ respective constituent documents. Management fees charged to the Farallon Funds typically are calculated as a percentage of capital under management (except with respect to certain Farallon Funds structured as designated-term private investment funds where management fees may be based on capital commitments or invested capital), generally range up to 1.0% per annum, but in certain cases are higher, and are typically payable and deducted from the assets of each such Farallon Fund quarterly in advance. From time to time, management fees may be paid to a Farallon Adviser as set forth in the relevant investment management agreement or constituent document of a Farallon Fund. Management fees based on capital under management will generally be prorated for any subscriptions or withdrawals by an investor that are effective other than as of the first or last day of the quarter. In the event of a distribution or withdrawal prior to the end of a quarter, Farallon will reimburse to the respective Farallon Fund a pro rata share of such management fees charged with respect to the distributed or withdrawn amount. Management fees for any managed account are established pursuant to any such managed account’s investment management agreement. Farallon has waived or reduced and may, in the future, waive or reduce management fees for certain classes or investors, including employees and affiliates of Farallon as well as their family members and trusts or other entities established for the benefit of such persons or their families, in its discretion. Incentive Compensation Incentive fees payable to Farallon or incentive allocations allocable to FPLLC vary by Farallon Fund and are established pursuant to the Farallon Funds’ respective constituent documents. For most open-ended Farallon Funds, incentive fees and incentive allocations generally are charged at year-end (or on an intra-year withdrawal date, if applicable) at a rate of 20% of net annual profits to such Farallon Fund, or to capital accounts maintained by such Farallon Funds for their investors. For this purpose, with respect to investments that are not Special Investments (as defined below), net profits generally include both realized gains and losses and unrealized appreciation and depreciation of securities held in the Farallon Funds’ portfolios, and with respect to Special Investments, net profits generally include only realized gains and losses and not unrealized appreciation and depreciation. For most open-ended Farallon Funds, incentive allocations generally will be charged at a rate of 10% instead of 20% for periods after an unrecovered loss year, which is a year over which net losses have been incurred in an investor’s capital account, until such investor’s capital account has recovered 250% of the net losses allocated to such account over such year, subject to certain adjustments, e.g., for withdrawals. One strategy-specific open-ended Farallon Fund charges an incentive allocation in excess of the return on a specific index (including on negative performance in excess of the index). Other Farallon Funds have different arrangements relative to incentive compensation. Certain investment-specific and strategy-specific closed-end Farallon Funds have distribution waterfalls whereby FPLLC is entitled to a 20% carried interest only after investors have received distributions equal to their capital contributions as of the time of distribution. Certain Farallon Funds have various preferred or threshold return hurdles that must be reached before FPLLC is entitled to such incentive compensation. Carried interest may be calculated on an investment-by-investment basis in respect of certain investment-specific Farallon Funds. From time to time, the carried interest allocable to FPLLC in respect of certain non-U.S. dollar- denominated investments may be calculated in the applicable foreign currency. All incentive compensation for managed accounts are subject to negotiation and established pursuant to each account’s investment management agreement. Farallon or FPLLC has waived or reduced and may, in the future, waive or reduce incentive fees and allocations for certain classes or investors, including employees and affiliates of Farallon, as well as their family members and trusts or other entities established for the benefit of such persons or their family members. Farallon or FPLLC has also waived or reduced and may, in the future, waive or reduce in its discretion incentive fees and allocations in respect of certain investors in connection with certain netting arrangements that they may have across multiple Farallon Funds. B. Payment of Fees Management fees typically are payable quarterly in advance and may be deducted from the assets of, or distributions payable by, a Farallon Fund, and incentive or performance-based fees or profit allocations are generally paid or allocated annually (or upon intra-year withdrawal dates) from the assets of the Farallon Funds or capital accounts maintained for their investors, or for certain Investment Partnerships which are structured as designated-term private investment funds, made as a distribution of proceeds or current income when available. Certain closed-end Farallon Funds also have the ability to call capital for the payment of fees. C. Additional Fees and Expenses To the extent permitted under the Farallon Funds’ constituent documents, the Farallon Funds are obligated to pay for all legal, auditing and accounting fees and expenses, tax preparation and tax compliance expenses, investment expenses (including, without limitation, the Farallon Funds’ share of costs and expenses attributable to sourcing, acquiring, evaluating, holding, ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 7: Types of Clients Farallon provides investment advice to the Farallon Funds, as described above in Item 4, managing equity capital for institutions such as endowments, foundations, charitable organizations and state and municipal government entities, and for high net worth individuals. The constituent documents for each Farallon Fund may set minimum amounts for investment by prospective investors. Farallon has waived, and reserves the right to modify or waive, the minimum investment amounts for the Farallon Funds from time to time. Minimum investment amounts for managed accounts will be determined on a case-by-case basis. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Revolution Medicines Inc | 1.3 | ||
| Amazon Com Inc | 0.9 | ||
| Microsoft Corp | 0.9 | ||
| Aon Corp | 0.8 | ||
| Bridgebio Pharma Inc | 0.7 | ||
| Protagonist Therapeutics Inc | 0.7 | ||
| Natera Inc | 0.6 | ||
| Exelixis Inc | 0.6 | ||
| Broadcom Inc | 0.6 | ||
| UnitedHealth Group Inc | 0.5 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Farallon Special Situations Master Fund III Non-US LP | [2024-06-10] | 964.6 M | |
| Filed 2025-05-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Farallon Special Situations Master Fund III US LP | [2024-06-10] | 217.4 M | |
| Filed 2025-05-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Farallon Special Situations Master X-VII LP | 2023-03-29 | 268.5 M | |
| HF | Farallon Co-Investment Master Fund LP | [2022-08-04] | 0.1 M | 49.8 M |
| Filed 2025-05-19 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Farallon Real Estate Institutional Partners IV LP | [2022-08-04] | 460.7 M | |
| Filed 2022-07-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Farallon Real Estate Partners IV LP | [2022-08-04] | 200.9 M | |
| Filed 2022-07-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Farallon Special Investment Institutional Partners IV LP | [2022-02-14] | 104.7 M | 100.0 M |
| Filed 2021-12-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Farallon Special Situations Master Credit IX LP | 2022-02-14 | 259.6 M | |
| HF | Farallon Healthcare Partners Master LP | [2021-08-03] | 510.5 M | 4,503.8 M |
| Filed 2025-07-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Farallon Capital F5 CC LP | 2021-03-30 | 295.4 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 66 | 52.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.1 |
| Total | 67 | 52.1 |
| By Discretionary | ||
| Discretionary | 67 | 52.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 67 | 52.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 21.9 | |
| United States Persons | 30.1 | |
| Total | 67 | 52.1 |
| Limited Partners | 2011 - 2026 |
|---|---|
| New Jersey Division of Investment | |
| Virginia Retirement System |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Grant Jackson | Director | 175 | 39 | |
| Martin Lang | Director | 161 | 31 | |
| Russell Burt | Director | 113 | 29 | |
| David Kim | Executive Officer | 88 | 7 | |
| Michael Fisch | Executive Officer | 42 | 5 | |
| Michael Linn | Executive Officer | 41 | 4 | |
| Daniel Hirsch | Executive Officer | 29 | 3 | |
| Cameron Hillyer | Executive Officer | 27 | 3 | |
| Thomas Steyer | Executive Officer | 21 | 3 | |
| Jason Moment | Executive Officer | 13 | 3 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0000909661] | |
| 3 | [0000909661] | |
| 4 | [0000909661] | |
| SC 13D | [0000909661] | |
| SC 13G | [0000909661] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $28.9B |
| Clients | 1 (63 non-US) |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 87DR6WT2MK1KMGUC7161 |
| Related People Network |
|---|
| 47 people file Form D offerings alongside this firm's people. |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Generation Bio Co GBIO
Common Stock
|
2020-06-16 | Conversion | 1,518,819 | ||
|
Generation Bio Co GBIO
Common Stock
|
2020-06-16 | Buy | 400,000 | $19.00 | 7,600,000 |
|
Generation Bio Co GBIO
Series C Preferred Stock · derivative
|
2020-06-16 | Conversion | 2,682,691 | ||
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 249,462 | $6.72 | 1,676,385 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 833,845 | $6.72 | 5,603,438 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 915,583 | $6.72 | 6,152,718 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 899,268 | $6.72 | 6,043,081 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 209,577 | $6.72 | 1,408,357 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 2,067,651 | $6.72 | 13,894,615 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 122,006 | $6.72 | 819,880 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2017-07-31 | Tender | 2,648,696 | $6.72 | 17,799,237 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 3,007 | $3.36 | 10,104 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 3,303 | $3.36 | 11,098 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 9,554 | $3.36 | 32,101 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 440 | $3.36 | 1,478 |
|
Nexvet Biopharma PLC NVET
Ordinary Share
|
2016-02-26 | Buy | 3,244 | $3.36 | 10,900 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 756 | $3.36 | 2,540 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 7,458 | $3.36 | 25,059 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-26 | Buy | 900 | $3.36 | 3,024 |
|
Nexvet Biopharma PLC NVET
Ordinary Shares
|
2016-02-25 | Buy | 65,694 | $3.18 | 208,907 |
| showing 20 of 163 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Marshall Wace North America LP
✚
|
NY | 58.87 B |
|
Blackstone Private Credit Strategies LLC
✚
|
NY | 57.92 B |
|
TA Associates Management LP
✚
|
MA | 55.07 B |
|
Veritas Capital Fund Management LLC
✚
|
NY | 53.81 B |
|
Blackstone Liquid Credit Advisors I LLC
✚
|
NY | 51.63 B |
|
Crescent Capital Group LP
✚
|
CA | 49.71 B |
|
ICG Investments Inc
✚
|
NY | 49.69 B |
|
Macquarie Infrastructure Partners Inc
✚
|
NY | 48.84 B |
|
Antares Capital Advisers LLC
✚
|
IL | 47.39 B |
|
Silver Point Capital LP
✚
|
CT | 46.23 B |